Brief: Radiopharm Theranostics To Start Rv-01 Study In 4Q25
28/07/2025 13:01
July 28 (Reuters) - Radiopharm Theranostics Ltd RAD.AX: RADIOPHARM THERANOSTICS RECEIVES IND APPROVAL FROM US FDA TO INITIATE PHASE I THERAPEUTIC CLINICAL STUDY TO TARGET B7H3 WITH BETABART (RV-01) RADIOPHARM THERANOSTICS LTD - TO START RV-01 STUDY IN 4Q25 Source text: ID:nGNX6vyWQC Further company coverage: RAD.AX (Reporting by Anshi Sancheti) ((Anshi.Sancheti@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%